Processa Pharmaceuticals (PCSA) Competitors $0.26 -0.08 (-23.97%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.25 -0.01 (-4.84%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. NKGN, IBIO, ABP, NXTC, PRPH, SYBX, MEIP, VYNE, TXMD, and FLGCShould you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include NKGen Biotech (NKGN), iBio (IBIO), Abpro (ABP), NextCure (NXTC), ProPhase Labs (PRPH), Synlogic (SYBX), MEI Pharma (MEIP), VYNE Therapeutics (VYNE), TherapeuticsMD (TXMD), and Flora Growth (FLGC). These companies are all part of the "pharmaceutical products" industry. Processa Pharmaceuticals vs. Its Competitors NKGen Biotech iBio Abpro NextCure ProPhase Labs Synlogic MEI Pharma VYNE Therapeutics TherapeuticsMD Flora Growth Processa Pharmaceuticals (NASDAQ:PCSA) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability. Do analysts recommend PCSA or NKGN? Processa Pharmaceuticals currently has a consensus price target of $6.00, suggesting a potential upside of 2,221.08%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Processa Pharmaceuticals is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Processa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer PCSA or NKGN? Processa Pharmaceuticals received 15 more outperform votes than NKGen Biotech when rated by MarketBeat users. CompanyUnderperformOutperformProcessa PharmaceuticalsOutperform Votes1560.00% Underperform Votes1040.00% NKGen BiotechN/AN/A Is PCSA or NKGN more profitable? NKGen Biotech's return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Processa PharmaceuticalsN/A -195.21% -163.06% NKGen Biotech N/A N/A -479.36% Does the media prefer PCSA or NKGN? In the previous week, Processa Pharmaceuticals had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Processa Pharmaceuticals and 0 mentions for NKGen Biotech. Processa Pharmaceuticals' average media sentiment score of 0.93 beat NKGen Biotech's score of 0.00 indicating that Processa Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Processa Pharmaceuticals Positive NKGen Biotech Neutral Which has higher earnings and valuation, PCSA or NKGN? Processa Pharmaceuticals has higher earnings, but lower revenue than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Processa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcessa PharmaceuticalsN/AN/A-$11.12M-$3.08-0.08NKGen Biotech$80K185.41-$82.94M-$2.45-0.13 Do institutionals and insiders hold more shares of PCSA or NKGN? 91.9% of Processa Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 9.6% of Processa Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, PCSA or NKGN? Processa Pharmaceuticals has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. SummaryProcessa Pharmaceuticals beats NKGen Biotech on 10 of the 15 factors compared between the two stocks. Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricProcessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.07M$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E Ratio-0.088.4626.7519.65Price / SalesN/A261.91403.98152.07Price / CashN/A65.8538.2534.64Price / Book0.066.526.964.59Net Income-$11.12M$143.26M$3.23B$248.23M7 Day Performance-14.01%-0.21%-1.22%-1.07%1 Month Performance4.66%10.62%6.34%2.59%1 Year Performance-85.23%3.63%33.05%13.50% Processa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAProcessa Pharmaceuticals2.7841 of 5 stars$0.26-24.0%$6.00+2,221.1%-85.2%$3.07MN/A-0.0820News CoverageHigh Trading VolumeNKGNNKGen Biotech0.8023 of 5 stars$0.34flatN/A-75.6%$15.28M$80K-0.07N/AIBIOiBio1.1096 of 5 stars$0.91-7.1%$4.30+370.2%-63.6%$15.11M$375K0.00100Gap DownHigh Trading VolumeABPAbproN/A$0.25+17.8%$4.00+1,514.2%N/A$15.06M$183K0.0015Positive NewsGap DownNXTCNextCure4.6462 of 5 stars$0.53+6.7%$3.50+562.3%-57.4%$14.82MN/A-0.2590Positive NewsShort Interest ↓High Trading VolumePRPHProPhase Labs1.2618 of 5 stars$0.36-0.4%N/A-92.8%$14.81M$5.85M-0.28130Short Interest ↑Gap DownSYBXSynlogic1.2633 of 5 stars$1.27+4.4%N/A-22.8%$14.80M$8K-0.3080Short Interest ↑MEIPMEI Pharma1.6754 of 5 stars$2.21+1.4%N/A-21.0%$14.72M$65.30M-0.39100News CoveragePositive NewsShort Interest ↑Gap DownVYNEVYNE Therapeutics2.4676 of 5 stars$0.96-4.1%$6.25+551.7%-60.9%$14.59M$605K-1.1230Short Interest ↑High Trading VolumeTXMDTherapeuticsMD1.7895 of 5 stars$1.25flatN/A-42.4%$14.47M$1.84M0.00420Positive NewsGap UpFLGCFlora Growth2.7116 of 5 stars$0.640.0%$4.00+525.2%-33.7%$14.44M$53.26M-0.65280Positive NewsGap Down Related Companies and Tools Related Companies NKGen Biotech Alternatives iBio Alternatives Abpro Alternatives NextCure Alternatives ProPhase Labs Alternatives Synlogic Alternatives MEI Pharma Alternatives VYNE Therapeutics Alternatives TherapeuticsMD Alternatives Flora Growth Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Processa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
